Small molecule · Antagonist of histamine H3 receptor (HRH3) · developed by Harmony
Pitolisant is an orally given histamine-3 (H3) receptor antagonist/inverse agonist. It acts on H3 receptors, which regulate histamine release in the brain, and it is studied in sleep disorders and other neurological conditions including Prader-Willi syndrome, myotonic dystrophy 1, idiopathic hypersomnia and restless legs syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 13, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05581576 | Phase 4 | Restless Legs Syndrome | Unknown | HRMY |
| NCT06366464 | Phase 3 | Prader-Willi Syndrome | Recruiting | HRMY |
| NCT05156047 | Phase 3 | Idiopathic Hypersomnia | Completed | HRMY |
| NCT04886518 | Phase 2 | Myotonic Dystrophy 1 | Completed | HRMY |
| NCT04257929 | Phase 2 | Prader-Willi Syndrome | Completed | HRMY |
| NCT07860736 | Phase 1 | Healthy Participants | Completed | HRMY |
| NCT07051252 | Phase 1 | Narcolepsy | Completed | HRMY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Excessive Daytime SleepinessHealthy ParticipantsIdiopathic HypersomniaMyotonic Dystrophy 1NarcolepsyPrader-Willi SyndromeRestless Legs Syndrome
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRMY page.
See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRMY catalysts and pipeline →